<DOC>
	<DOC>NCT00380263</DOC>
	<brief_summary>To investigate headache score and accompanying symptoms during and after infusion of PACAP38 i migraine patients</brief_summary>
	<brief_title>PACAP38Â´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow</brief_title>
	<detailed_description>To investigate headache score and accompanying symptoms during and after infusion of PACAP38 Changes in regional cerebral blood flow (rCBF) in the area supplied by middle cerebral artery (MCA), blood flow in MCA, diameter of the superficial temporal artery (STA) and radial artery (RA)</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
	<criteria>Healthy migraine patient without aura Aged 1850 50100 kg Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen. Tension type headache more than five times/month Other primary headaches Daily medication except contraceptives Drug taken within 4 times the halflife for the specific drug except contraceptives Pregnant or lactating women Exposure to radiation within the last year Headache within the last 48 hours before start of trial Hypertension Hypotension Respiratory or cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>